Takeda Pharmaceutical Co. Ltd. is in negotiations for a sale of its assets in Russia to Stada Arzneimittel Aktiengesellschaft and for divesting its assets in the Middle East and Africa to Acino International AG, Bloomberg News reported Oct. 10, citing anonymous sources.
Germany-based pharmaceuticals company Stada, which is owned by asset management firms Cinven Ltd. and Bain Capital LP, is in discussions with the Japanese company for its over-the-counter and prescription-drug assets in Russia, the news outlet noted.
Takeda is also close to finalizing a deal with private Swiss pharmaceutical company Acino International, which is owned by private equity companies Nordic Capital and Avista Capital Partners LP, for its assets in the Middle East and Africa.
Representatives for Takeda, Stada, Cinven, Bain, Nordic Capital and Avista declined to comment, according to Bloomberg News.
Takeda is also looking for buyers to sell its portfolio of over-the-counter and prescription drugs in emerging markets and western Europe in separate transactions, Bloomberg News reported in September.
The Japanese drugmaker said in 2018 that it plans to sell about $10 billion in assets to reduce debt and simplify its portfolio after acquiring Shire PLC for £46 billion.
